Brooke Fruman supports clients with research and analysis that span a variety of healthcare stakeholders.
She applies her background in health policy and public health to assist clients as they strategize marketplace and policy decisions.
Prior to joining Avalere, Brooke held a variety of internship positions, most recently as a health policy associate at the Maryland General Assembly. In this position, Brooke conducted extensive research on health policy legislation in Maryland and evaluated the impact of policies that were established in response to the COVID-19 public health emergency, focusing on telehealth services. Additionally, Brooke has also held positions as a consulting services intern at RAINN and as a graduate teaching assistant at the University of Maryland School of Public Health.
Brooke has a BS in community health and an MPH with a concentration in health policy analysis and evaluation from the University of Maryland.
Authored Content
IRA Medicare provisions, increased focus on price regulations including Most-Favored Nation pricing, and broad fiduciary pressures have ripple effects across the healthcare ecosystem.
Draft guidance for IPAY 2028 Medicare drug price negotiation includes the first-time inclusion of Part B drugs, refinement to MFP effectuation, and considerations around what qualifies as a single-source drug.
Several pathways exist to effectuate the MFP for Part B negotiation with benefits and drawbacks for stakeholders across the drug supply chain.
With less than a year until the first MFPs take effect, stakeholder concerns remain, especially as it relates to 340B duplicate discount risk.
SAD list placement will inform the channel that providers and patients use to access a therapy.
Manufacturers impacted by the Part B discarded drug refund policy should assess claims billing and adjudication patterns to inform mitigation strategy.
In CY 2024 rulemaking, CMS proposes operational clarification to the discarded drug refund policy finalized last year.
Starting July 1, providers must report the JZ modifier on all claims for single-use Part B drugs when applicable, including for products billed with an NOC code.
Avalere survey finds 65% of providers experience challenges associated with billing, coding, and reimbursement for RPM.
Manufacturers should assess liability to drug waste refunds and engage with CMS as it considers an increased applicable percentage for specific product types.
Among LIS Medicare patients using oral/IV therapy for kidney cancer, social risk factors may impact adherence, even when the OOP burden is reduced.
Assessing barriers that impact patient access to obesity care and educating stakeholders on how to mitigate them can advance solutions toward improving care.
Digital health tools are an increasingly important component of complete patient support solutions that can optimize patient care, yet they are currently underutilized.
The COVID-19 pandemic has catalyzed the growth of hybrid care delivery models, highlighting the need for clinical guidance and stakeholder agility.
The MPFS final rule implements the discarded drug refund requirement for certain single-use physician-administered drugs, presenting risks to manufacturers of these products.
Avalere found that characteristics of Medicare patients’ place of residence influenced adherence to combination treatment regimens for multiple myeloma.
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
As manufacturers prepare for discarded drug rebates to begin in 2023, an Avalere analysis identified 39 drugs at risk for rebates totaling $151 million.
The digital health technologies (DHTs) market is projected to grow from $3.5 billion in 2020 to $23.5 billion by 2030. Stakeholders must navigate complex pathways as the FDA develops regulatory frameworks for DHTs.
A recent Pear Therapeutics–Avalere survey of 30 payers and 10 employer self-insured groups identified numerous insights to direct future efforts for broader adoption and coverage of prescription digital therapeutics (PDTs).
New analysis from Avalere finds that in 2022 more Medicare Advantage plans will offer non-medical supplemental benefits, such as meals, nutrition, transportation, and in-home support services, at a $0 premium.
Prescription Digital Therapeutics (PDTs) are a growing and unique treatment modality that can provide expanded options for treatment to patients. As the landscape for these treatments develop across multiple therapeutic areas, challenges related to coverage, reimbursement, and access will need to be solved to advance broader adoption and utilization across key stakeholders.